

Edgar Filing: Stem Cell Therapy International, Inc. - Form 8-K

("SCII"), entered into a Reorganization and Stock Purchase Agreement (the "Agreement") with Histostem Co., Ltd., a Korean company ("Histostem"). Pursuant to the Agreement, SCII will acquire ninety five percent (95%) of the issued and outstanding stock of Histostem from Histostem's shareholders, and Histostem's shareholders will acquire a controlling interest in SCII. The definitive agreement calls for closing of the acquisition by April 30, 2008, or sooner if the investment bankers working on the financial aspects of the transaction are able to close the funding round earlier. The newly combined entities will be held approximately 60% by Histostem and 40% by the existing shareholders of Stem Cell Therapy International. Upon completion of the acquisition, Stem Cell Therapy International will be renamed "AmStem International Corp." and will seek a new symbol on the over-the-counter bulletin board. Until such time, Stem Cell will continue to trade under the symbol SCII.OB.

Histostem, Co., Ltd. started in Seoul, Korea in 2000. To date it has treated more than 500 patients with stem cells and currently has 56 full time employees and 28 part-time employees. Histostem's intellectual property portfolio consists of five patents that have been granted and 6 patents pending. To management's knowledge, Histostem is one of the very few stem cell companies in the world currently earning several million dollars in income from its products and technology. Histostem maintains a website at http://www.histostem.cokr/english/english_1.htm.

Upon completion of the definitive agreement, management intends to take the research data that the Korean FDA already approved and submit it to the U.S. FDA, with the objective of getting the U.S. FDA approval in advance of other companies now researching umbilical stem cell treatments for a variety of different diseases.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS

(c) Exhibits.

10.36 Reorganization and Stock Purchase Agreement between Stem Cell Therapy International, Inc., and Histostem Co., Ltd.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

STEM CELL THERAPY INTERNATIONAL, INC.
(Registrant)

Dated: March 17, 2008

By: /s/Calvin Cao

Calvin Cao
Chief Executive Officer